BRAINSTORM CELL THERAPEUTICS INC. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Owns After | Date |
|---|---|---|---|---|---|---|---|
| Dagher Ibrahim B. | Chief Medical Officer | Award / Grant | 50,000 | — | — | 66,849 | Jan 1, 2025 |
| Lebovits Chaim | President & CEO | Award / Grant | 120,000 | — | — | 200,960 | Jan 1, 2025 |
| FRENKEL JACOB A | — | Award / Grant | 40,000 | — | — | 43,777 | Jan 1, 2025 |
| Polverino Anthony J. | — | Award / Grant | 24,000 | — | — | 25,730 | Jan 1, 2025 |
| Yablonka Uri | EVP & Chief Business Officer | Award / Grant | 20,000 | — | — | 68,464 | Jan 1, 2025 |
| Patlis Alla | See Remarks | Award / Grant | 40,000 | — | — | 44,349 | Jan 1, 2025 |
| Naor Nir | — | Award / Grant | 30,666 | — | — | 31,465 | Jan 1, 2025 |
| Lindborg Stacy | — | Award / Grant | 20,000 | — | — | 48,229 | Jan 1, 2025 |
| HARTOUNIAN HARTOUN | EVP, Chief Operating Officer | Award / Grant | 50,000 | — | — | 52,000 | Jan 1, 2025 |
| Bairu Menghisteab | — | Award / Grant | 24,000 | — | — | 24,000 | Jan 1, 2025 |
| ARBEL IRIT | — | Award / Grant | 30,666 | — | — | 41,054 | Jan 1, 2025 |
| Lebovits Chaim | President & CEO | Purchase | 22,000 | $0.23 | $5,060 | 1,186,865 | Oct 1, 2024 |
| Dagher Ibrahim B. | Chief Medical Officer | Sale | 63,000 | $0.35 | $22,050 | — | Jul 19, 2024 |
| HARTOUNIAN HARTOUN | EVP, Chief Operating Officer | Award / Grant | 30,000 | — | — | 30,000 | Jun 24, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 15,000 | $0.52 | $7,800 | 1,164,865 | May 28, 2024 |
| Lebovits Chaim | President & CEO | Purchase | 15,000 | $0.52 | $7,800 | 1,164,865 | May 28, 2024 |
| Lebovits Chaim | President & CEO | Purchase | 25,000 | $0.58 | $14,500 | 1,124,865 | May 22, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 25,000 | $0.64 | $16,000 | 1,149,865 | May 21, 2024 |
| Lebovits Chaim | President & CEO | Purchase | 20,000 | $0.47 | $9,400 | 1,079,865 | May 11, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 10,000 | $0.49 | $4,900 | 1,099,865 | May 10, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 66,300 | $0.37 | $24,531 | 1,059,865 | May 7, 2024 |
| Lebovits Chaim | President & CEO | Purchase | 66,300 | $0.37 | $24,531 | 1,059,865 | May 7, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 135,000 | $0.38 | $51,300 | 993,565 | May 6, 2024 |
| Lebovits Chaim | President & CEO | Purchase | 135,000 | $0.38 | $51,300 | 993,565 | May 6, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 15,000 | $0.52 | $7,800 | 858,565 | Apr 19, 2024 |
| Lebovits Chaim | President & CEO | Purchase | 15,000 | $0.52 | $7,800 | 858,565 | Apr 19, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 130,000 | $0.55 | $71,500 | 728,493 | Apr 18, 2024 |
| Lebovits Chaim | President & CEO | Purchase | 130,000 | $0.55 | $71,500 | 728,493 | Apr 18, 2024 |
| Lindborg Stacy | Co-Chief Executive Officer | Award / Grant | 241,935 | — | — | 423,435 | Mar 11, 2024 |
| Yablonka Uri | EVP & Chief Business Officer | Award / Grant | 109,426 | — | — | 126,969 | Mar 11, 2024 |
| Patlis Alla | See Remarks | Award / Grant | 65,246 | — | — | 65,246 | Mar 11, 2024 |
| Lebovits Chaim | President & CEO | Award / Grant | 305,198 | — | — | 598,493 | Mar 11, 2024 |
| Lindborg Stacy | Co-Chief Executive Officer | Purchase | 11,500 | $1.77 | $20,355 | 181,500 | Sep 1, 2023 |
| Lindborg Stacy | Co-Chief Executive Officer | Award / Grant | 35,000 | — | — | 170,000 | Aug 2, 2023 |
| Lebovits Chaim | President & CEO | Award / Grant | 31,185 | — | — | 293,295 | Aug 2, 2023 |
| Naor Nir | — | Award / Grant | 11,999 | — | — | 11,999 | Jun 19, 2023 |
| Taylor Kirk | Chief Medical Officer | Award / Grant | 35,000 | — | — | 35,000 | May 1, 2023 |
| Lebovits Chaim | President & Co-CEO | Award / Grant | 75,000 | — | — | 262,110 | Apr 20, 2023 |
| Lindborg Stacy | Co-Chief Executive Officer | Award / Grant | 75,000 | — | — | 135,000 | Apr 20, 2023 |
| Lindborg Stacy | Co-Chief Executive Officer | Award / Grant | 35,000 | — | — | 60,000 | Dec 7, 2022 |
| Lebovits Chaim | Chief Executive Officer | Award / Grant | 31,185 | — | — | 187,110 | Sep 18, 2022 |
| Kern Ralph Dr. | COO and Chief Medical Officer | Award / Grant | 35,885 | — | — | 223,310 | Mar 6, 2022 |
| Polverino Anthony J. | — | Award / Grant | 3,882 | — | — | 25,960 | Feb 1, 2022 |
| TAUB MALCOLM S | — | Award / Grant | 12,000 | — | — | 77,332 | Dec 15, 2021 |
| Polverino Anthony J. | — | Award / Grant | 2,000 | — | — | 22,078 | Dec 15, 2021 |
| Almenoff June Sherie | — | Award / Grant | 2,000 | — | — | 6,000 | Dec 15, 2021 |
| Kern Ralph Dr. | COO and Chief Medical Officer | Award / Grant | 35,885 | — | — | 187,425 | Dec 10, 2021 |
| Lebovits Chaim | Chief Executive Officer | Award / Grant | 31,185 | — | — | 155,925 | Dec 10, 2021 |
| TAUB MALCOLM S | — | Award / Grant | 12,000 | — | — | 65,332 | Dec 10, 2021 |
| Polverino Anthony J. | — | Award / Grant | 2,216 | — | — | 18,078 | Dec 10, 2021 |